CTXR
The numbers are doing the talking
Citius Oncology’s fiscal second-quarter update wasn’t just a spreadsheet dump — it was basically a “look, the launch is real” moment. The company said net revenue hit $5.6 million in the first half of fiscal 2026 as LYMPHIR® continues rolling out, which is the kind of progress investors want to see when a biotech goes from science project to sales story.
Why this matters
Biotech launches can be a little like assembling IKEA furniture with one missing screw: the product may be approved, but getting actual usage, reimbursement, and formulary access is where the drama lives. Citius says broad payer coverage is in place, reimbursement denials are zero so far, and 83% of target accounts are either on formulary or under review. That’s not victory lap territory, but it is a meaningful sign that the commercial machine is grinding forward.
The cash cushion helps too
The company also said it has secured up to $36.5 million in debt and equity capital. That matters because early-stage commercialization can burn cash faster than a streaming subscription free trial. More funding gives Citius a better shot at keeping the launch on the rails while it tries to convert coverage into prescriptions and prescriptions into recurring revenue.
Big picture
For investors, this is less about one quarter and more about whether LYMPHIR can turn into a legit growth engine. The launch update says the story is moving in the right direction — coverage up, access improving, and money in the bank to keep pushing. Now comes the annoying part: proving the momentum is durable, not just a good-looking first lap.